Drugmaker Eli Lilly and Co. spent about $2.3 million in the first quarter of 2010 lobbying the federal government on health care reform, Medicare reimbursement and trade issues among other topics.
The Indianapolis drugmaker also lobbied on financial derivatives, the Patent Reform Act and the Child Nutrition Act reauthorization, according to a lobbying report filed with the House of Representatives.
The $2.3 million Lilly spent in the January-March period represented a drop of more than 30 percent drop from the $3.4 million it spent in the first quarter of 2009.
Besides Congress, Lilly lobbied the Patent & Trademark Office, the U.S. Trade Representative, the Food and Drug Administration, and the departments of Commerce, State, Agriculture, and Health and Human Services.